Caelus Health

Foundation date

11-1-2017

Sector

#Biotechnology - Therapeutics

Therapeutic areas

Caelus Health is a biotech company developing an entirely new class of Microbiome Therapeutics for the reduction of insulin resistance and prevention of Type 2 Diabetes (T2DM) in people with metabolic syndrome.The company is dedicated to the commercialisation of functional food and pharmabiotic products for the prevention and early treatment of cardio metabolic diseases – based on the strong correlation between the intestinal microbiome and health.  

Upcoming events

Latest news

  • Mithra Announces Shelf Life Extension for Myring™ to 36 Months

    Tuesday August 4th 2020

  • Antelope Dx receives 2,2M euro grant from VLAIO to expand capabilities for its home testing device

    Tuesday August 4th 2020

  • A regulatory network driving heterogeneity in melanoma cells

    Tuesday August 4th 2020